All In Biotech

Drug Trial Radar · NCT07566156

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Mar 31, 2030

Study completion Feb 29, 2032

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Pfizer
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

Conditions

  • Urothelial Cancer
  • Urinary Bladder Neoplasms

Interventions

  • Enfortumab vedotinDrug

    Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.

  • Conventional RadiotherapyRadiation

    64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes.

  • Hypofractionated RadiotherapyRadiation

    55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only.

  • CisplatinDrug

    40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation.

  • FluorouracilDrug

    500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.

  • Mitomycin CDrug

    12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.

  • GemcitabineDrug

    100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation

  • PembrolizumabDrug

    IV infusion on Day 1 of every 3-week cycle up to cycle 17.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)Time frame: Up to approximately 45.5 months
  2. Overall Survival (OS)Time frame: Up to approximately 60 months

Locations

37 sites in 6 countries. Site status is shown where the registry gives one.

  • Arkansas Urology

    Little Rock, Arkansas · Recruiting

  • Samsun Clinic - Ridley-Tree Cancer Center

    Santa Barbara, California · Recruiting

  • Rocky Mountain Cancer Center

    Aurora, Colorado · Recruiting

  • Medical Oncology Hematology Consultants

    Newark, Delaware · Recruiting

  • Hope and Healing Clinical Research LLC

    Hinsdale, Illinois · Recruiting

  • Hope and Healing Clinical Research LLC

    New Lenox, Illinois · Recruiting

  • Illinois Cancer Specialists

    Niles, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • Comprehensive Urology

    Royal Oak, Michigan · Recruiting

  • Missouri Cancer Associates

    Columbia, Missouri · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Comprehensive Cancer Centers of Nevada - Southwest

    Las Vegas, Nevada · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Oncology Hematology Care Clinical Trials, LLC

    Fairfield, Ohio · Recruiting

  • Williamette Valley Cancer Institute and Research Center

    Eugene, Oregon · Recruiting

  • Compass Oncology - West

    Tigard, Oregon · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology

    Austin, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Tyler, Texas · Recruiting

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Site BR01087

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Site BR01093

    Barretos, São Paulo, Brazil · Recruiting

  • Site BR01099

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Site CA01194

    Chicoutimi, Quebec, Canada · Recruiting

  • Site CA01052

    Montreal, Quebec, Canada · Recruiting

  • Site CA01071

    Montreal, Quebec, Canada · Recruiting

  • Site FR01078

    Nîmes, France · Recruiting

  • Site KR01113

    Daegu, South Korea · Recruiting

  • Site KR01063

    Seongnam-si, South Korea · Recruiting

  • Site KR01061

    Seoul, South Korea · Recruiting

  • Site KR01064

    Seoul, South Korea · Recruiting

  • Site KR01065

    Seoul, South Korea · Recruiting

  • Site KR01084

    Seoul, South Korea · Recruiting

  • Site KR01085

    Seoul, South Korea · Recruiting

  • Site KR01062

    Goyang-si, Gyeonggi-do, South Korea · Recruiting

  • Site TW01117

    Kaohsiung City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.